SCHEMBL5565204

SCHEMBL5565204

COc1cc2ncnc(Nc3ccc(C)c(C)c3)c2cc1OC

nearest known ligand 0.79

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.79
RET P07949 4/20 0.79
KIF5B P33176 2/20 0.79
EGFR P00533 17/20 0.78
CLK1 P49759 1/20 0.78
ABCG2 Q9UNQ0 1/20 0.78
LCK P06239 5/20 0.76
FLT1 P17948 1/20 0.70
GAK O14976 1/20 0.70
RIPK2 O43353 1/20 0.70
STK10 O94804 1/20 0.70
FLT3 P36888 1/20 0.70
JAK3 P52333 1/20 0.70
AAK1 Q2M2I8 1/20 0.70
Q6ZSR9 Q6ZSR9 1/20 0.70
SLK Q9H2G2 1/20 0.70
IRAK4 Q9NWZ3 1/20 0.70
RPS6KA6 Q9UK32 1/20 0.70
ALK Q9UM73 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865262 0.88 EGFR (0.81) KDRRETKIF5BEGFRCLK1
SCHEMBL5651286 0.88 KDR (1.00) KDRRETKIF5BEGFRCLK1
SCHEMBL6783334 0.88 KDR (0.74) KDRRETKIF5BEGFRCLK1
SCHEMBL6068633 0.88 KDR (0.82) KDRRETKIF5BEGFRCLK1
SCHEMBL5565137 0.87 EGFR (1.00) KDRRETKIF5BEGFRCLK1
Hydrochloric Acid SCHEMBL7859467 0.87 KDR (0.98) KDRRETKIF5BEGFRCLK1
SCHEMBL14979614 0.87 EGFR (0.71) KDRRETKIF5BEGFRCLK1
SCHEMBL5473778 0.86 EGFR (0.80) KDRRETKIF5BEGFRCLK1
Hydrochloric Acid SCHEMBL5473795 0.85 EGFR (0.80) KDRRETKIF5BEGFRCLK1
SCHEMBL5473780 0.85 EGFR (0.78) KDRRETKIF5BEGFRCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-9353116-B2 Methods and compositions for kinase inhibition THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-05-31 US disclosed
US-20130137708-A1 METHODS AND COMPOSITIONS FOR KINASE INHIBITION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-05-30 US disclosed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137708-A1 METHODS AND COMPOSITIONS FOR KINASE INHIBITION SRC, ABL1, LCK KDR 1851/4885RET 120/4885KIF5B 1176/4885
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT KDR 2712/4885RET 2776/4885KIF5B 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.